- Naranj Research Desk
- 🇸🇦 Saudi Stock Market
- 🇺🇸 USA Stock Market
| Metric | Q1 FY26 (Feb '26) | Q4 FY25 (Nov '25) | Q1 FY25 (Feb '25) | QoQ Change | YoY Change |
|---|---|---|---|---|---|
| Total Revenue | $6.25 M | $13.58 M | $18.45 M | ▼ 54.0% | ▼ 66.1% |
| R&D Expenses | $84.1 M | ~$79.3 M | $70.2 M | ▲ 6.0% | ▲ 19.8% |
| G&A Expenses | $14.6 M | ~$13.6 M | $12.2 M | ▲ 7.4% | ▲ 19.7% |
| Operating Loss | $(92.5) M | ~$(79.3) M | $(64.0) M | ▼ 16.6% | ▼ 44.5% |
| Net Loss | $(87.2) M | ~$(65.8) M | $(57.5) M | ▼ 32.5% | ▼ 51.7% |
| Diluted EPS | $(0.79) | ~$(0.75) | $(0.67) | ▼ 5.3% | ▼ 17.9% |
NRIX — NASDAQ —
| Indicator | Value | Zone |
|---|---|---|
| RSI-14 | 76.04 | Overbought |
| CCI-14 | 80.31 | Neutral |
| ROC | 13.17 | Positive |
| Stochastic RSI | 84.72 | Overbought |
| William %R | -4.32 | Overbought |
| EMA | Value | Stock Position |
|---|---|---|
| 5 EMA | 91.05 | Above |
| 10 EMA | 89.62 | Above |
| 20 EMA | 87.55 | Above |
| 50 EMA | 82.69 | Above |
| 100 EMA | 78.89 | Above |
| 200 EMA | 75.91 | Above |
Based on our swing stock trading advice in USA, Nurix Therapeutics stock price target will be USD 25 - USD 25.2 in the next 12-14 trading sessions.
Nurix Therapeutics, founded in 2009 and headquartered in Brisbane, California, is a clinical-stage biopharmaceutical company developing targeted cancer and immune disease therapies using protein degradation technology. Its pipeline includes experimental treatments for blood cancers, autoimmune disorders, and inflammatory diseases, supported by strategic partnerships with Gilead Sciences, Sanofi, and Pfizer.
| Metric | Q1 FY26 (Feb '26) | Q4 FY25 (Nov '25) | Q1 FY25 (Feb '25) | QoQ Change | YoY Change |
|---|---|---|---|---|---|
| Total Revenue | $6.25 M | $13.58 M | $18.45 M | ▼ 54.0% | ▼ 66.1% |
| R&D Expenses | $84.1 M | ~$79.3 M | $70.2 M | ▲ 6.0% | ▲ 19.8% |
| G&A Expenses | $14.6 M | ~$13.6 M | $12.2 M | ▲ 7.4% | ▲ 19.7% |
| Operating Loss | $(92.5) M | ~$(79.3) M | $(64.0) M | ▼ 16.6% | ▼ 44.5% |
| Net Loss | $(87.2) M | ~$(65.8) M | $(57.5) M | ▼ 32.5% | ▼ 51.7% |
| Diluted EPS | $(0.79) | ~$(0.75) | $(0.67) | ▼ 5.3% | ▼ 17.9% |
NRIX — NASDAQ —
| Indicator | Value | Zone |
|---|---|---|
| RSI-14 | 76.04 | Overbought |
| CCI-14 | 80.31 | Neutral |
| ROC | 13.17 | Positive |
| Stochastic RSI | 84.72 | Overbought |
| William %R | -4.32 | Overbought |
| EMA | Value | Stock Position |
|---|---|---|
| 5 EMA | 91.05 | Above |
| 10 EMA | 89.62 | Above |
| 20 EMA | 87.55 | Above |
| 50 EMA | 82.69 | Above |
| 100 EMA | 78.89 | Above |
| 200 EMA | 75.91 | Above |
Based on our swing stock trading advice in USA, Nurix Therapeutics stock price target will be USD 25 - USD 25.2 in the next 12-14 trading sessions.
